{"schema_version":"secwatch.filing_event.v1","accession":"0001815776-24-000069","form_type":"8-K","ticker":"LENZ","cik":"0001815776","company_name":"LENZ Therapeutics, Inc.","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.786721+00:00","generated_at":"2026-05-30T04:44:42.500859+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"LENZ Therapeutics Q3 net loss $10.2M, cash $217.2M; LNZ100 NDA accepted, PDUFA Aug 8, 2025","bullets":["Net loss $10.2M ($0.38/share) for Q3 2024 vs $18.9M ($9.62/share) in Q3 2023.","Cash, equivalents and marketable securities $217.2M as of Sept 30, 2024; cash runway to post-launch positive operating cash flow.","FDA accepted NDA for LNZ100 (aceclidine) for presbyopia; PDUFA target action date Aug 8, 2025.","Positive topline Phase 3 data from China: 74% of patients achieved 3-line or greater improvement at 3 hours (p<0.0001).","Completed $30M private placement with Ridgeback Capital in July 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001815776-24-000069","json":"https://secwatch.observer/filing/0001815776-24-000069.json","markdown":"https://secwatch.observer/filing/0001815776-24-000069.md","text":"https://secwatch.observer/filing/0001815776-24-000069.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815776/000181577624000069/0001815776-24-000069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815776/000181577624000069/lenz-20241106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:44:42.500859+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}